← Browse by Condition
Medical Condition

glioblastoma multiforme gbm

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for glioblastoma multiforme gbm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — glioblastoma multiforme gbm Clinical Trials

How many clinical trials are currently recruiting for glioblastoma multiforme gbm?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for glioblastoma multiforme gbm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for glioblastoma multiforme gbm?
glioblastoma multiforme gbm research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a glioblastoma multiforme gbm clinical trial?
Eligibility criteria for glioblastoma multiforme gbm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
3
Top Sponsors
Institute of Cancer Research, United Kingdom 1 trial
Black Diamond Therapeutics, Inc. 1 trial
Northwell Health 1 trial

Recruiting Clinical Trials

NCT07391215 Phase 1, Phase 2
Recruiting
5G-PEARL: Paxalisib in Malignant Brain Tumours
Enrollment
64 pts
Location
United Kingdom
Sponsor
Institute of Cancer Research, ...
View Trial →
NCT07326566 Phase 2
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Enrollment
162 pts
Location
United States
Sponsor
Black Diamond Therapeutics, In...
View Trial →
NCT03213002 Phase 1, Phase 2
Recruiting
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Enrollment
67 pts
Location
United States
Sponsor
Northwell Health
View Trial →

Related Conditions

brain cancer (2) malignant primary gliomas (1) glioblastoma gbm (1) newly diagnosed glioblastoma (1) gbm (1) glioma (1) central nervous system diseases (1) glioblastoma (1) glioma of brain (1) glioblastoma adult (1) brain tumor (1) brain tumor primary (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology